An anonymous $50 million donation just landed at Mass General Brigham, aimed squarely at accelerating gene and cell therapy work across its cancer institute and the broader system. The money is intended to expand clinical trials and the infrastructure that helps experimental treatments move from the lab to patient care, arriving as the Boston health system sharpens its own cancer strategy.
The gift, from donors who are choosing to stay out of the spotlight, will go toward advancing gene and cell therapy research at the Mass General Brigham Cancer Institute and across the system, according to the Boston Business Journal. The outlet reported that the funding is earmarked for clinical trials and research facilities, but the benefactors themselves are keeping their names under wraps.
What the gift will fund
Mass General Brigham’s Gene and Cell Therapy Institute already brings together investigators, clinics and early phase trial infrastructure to develop cell based and gene editing treatments, and leaders expect this new funding to help scale those pipelines. As Mass General Brigham notes, the institute backs investigator driven “spark” grants and translational projects that aim to move discoveries into first in human studies, and the latest donation is set to build on that existing platform.
Why this matters in Boston
The new money plugs into a broader push by the system to build its own cancer platform. Mass General Brigham announced a separate $400 million investment last year to create a new cancer institute as it prepares for the end of its partnership with the Dana Farber Cancer Institute. That plan, which includes expanded outpatient and research space and large philanthropic commitments, is designed to help the system run more trials and keep cancer care inside its network, according to The Boston Globe…